1.93 USD
↗ 0.02 (1.05%)AT CLOSE (11:59 AM EDT)
BioVie, Inc. Common Stock
BIVINASDAQ • USD
1.93
↘ 0.01 (0.26%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
1.93
↘ 0.01 (0.26%)
Market: CLOSED
BioVie, Inc. Common Stock (BIVI) trades at $1.93 per share. BIVI shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics suggest BIVI is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Sep 11, 2026.
Open?$1.92
High?$2.02
Low?$1.91
Prev. Close?$1.91
Volume?170.8K
Avg. Volume?9.5M
VWAP?$1.97
Rel. Volume?0.02x
Bid / Ask
Bid?$1.91 × 1.1K
Ask?$1.99 × 100
Spread?$0.08
Midpoint?$1.95
Valuation & Ratios
Market Cap?16.3M
Shares Out?8.5M
Float?7.1M
Float %?94.0%
P/E Ratio?N/A
P/B Ratio?1.59
EPS?-$2.62
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Employees
13
Market Cap
16.1M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-01-14
Address
680 W NYE LANE
CARSON CITY, NV 89703
Phone: 775-888-3162
CARSON CITY, NV 89703
Phone: 775-888-3162
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?63
Piotroski F-Score?0/9Weak
Altman Z-Score?-38.73Distress
Confidence?44%Low
Short InterestHigh
Short % of Float?12.48%High
Short Interest?884.7K
Days to Cover?1.0
Free Float7.1M
Avg Daily Volume11.8M
Settlement Date2026-08-31
Financial Health
Current Ratio?3.59Strong
Quick Ratio?3.59Strong
Cash Ratio?2.37Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.59CHEAP▾
Peers100
S&P85
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.3CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-215.3%WEAK▾
S&P3
ROA?-155.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-19024806
Enterprise Value?$7.3M
Fundamentals ratios updated end of day